Amélie Tétu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amélie Tétu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Brigitte Boilard
Department of Pharmacy, Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada
1 shared publicationCédric Gasse
Department of Social and Preventive Medecine, Faculty of Medecine, Université Laval, Québec, QC, Canada
1 shared publication- Emmanuel Bujold
Department of Obstetrics and Gynecology. Research Center of CHU de Québec - Laval University, Quebec City, Canada
1 shared publication - Geneviève Blanchet
Department of Obstetrics and Gynecology, Faculty of Medecine, Université Laval, Québec, QC, Canada
1 shared publication Josée Mailhot
Research Center of the CHU de Québec, Université Laval, Québec, QC, Canada
1 shared publicationMarie-Noëlle Delorme
Direction of Nursing, Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Québec, Canada
1 shared publication
Latest Publications
- 9 November 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 88-95
Application of the Failure Mode and Effects Analysis (FMEA) to identify vulnerabilities and opportunities for improvement prior to implementing a computerized prescription order entry (CPOE) system in a university hospital oncology clinic
Introduction: Prior to implementing a new computerized prescription order entry (CPOE) application, the potential risks associated with this system were assessed and compared to those of paper-based prescriptions. The goal of this study is to identify the vulnerabilities of the CPOE process in order to adapt its design and prevent these potential risks. Methods and materials: Failure mode and effects analysis (FMEA) was used as a prospective risk-management technique to evaluate the chemotherapy medication process in a university hospital oncology clinic. A multidisciplinary team assessed the process and compared the critical steps of a newly developed CPOE application versus paper-based prescriptions. The potential severity, occurrence and detectability were assessed prior to the implementation of the CPOE application in the clinical setting. Results: The FMEA led to the identification of 24 process steps that could theoretically be vulnerable, therefore called failure modes. These failure modes were grouped into four categories of potential risk factors: prescription writing, patient scheduling, treatment dispensing and patient follow-up. Criticality scores were calculated and compared for both strategies. Three failure modes were prioritized and led to modification of the CPOE design. Overall, the CPOE pathway showed a potential risk reduction of 51% compared to paper-based prescriptions. Conclusion: FMEA was found to be a useful approach to identify potential risks in the chemotherapy medication process using either CPOE or paper-based prescriptions. The e-prescription mode was estimated to result in less risk than the traditional paper mode.
- 9 November 2021
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 88-95
Application of the Failure Mode and Effects Analysis (FMEA) to identify vulnerabilities and opportunities for improvement prior to implementing a computerized prescription order entry (CPOE) system in a university hospital oncology clinic
Introduction: Prior to implementing a new computerized prescription order entry (CPOE) application, the potential risks associated with this system were assessed and compared to those of paper-based prescriptions. The goal of this study is to identify the vulnerabilities of the CPOE process in order to adapt its design and prevent these potential risks. Methods and materials: Failure mode and effects analysis (FMEA) was used as a prospective risk-management technique to evaluate the chemotherapy medication process in a university hospital oncology clinic. A multidisciplinary team assessed the process and compared the critical steps of a newly developed CPOE application versus paper-based prescriptions. The potential severity, occurrence and detectability were assessed prior to the implementation of the CPOE application in the clinical setting. Results: The FMEA led to the identification of 24 process steps that could theoretically be vulnerable, therefore called failure modes. These failure modes were grouped into four categories of potential risk factors: prescription writing, patient scheduling, treatment dispensing and patient follow-up. Criticality scores were calculated and compared for both strategies. Three failure modes were prioritized and led to modification of the CPOE design. Overall, the CPOE pathway showed a potential risk reduction of 51% compared to paper-based prescriptions. Conclusion: FMEA was found to be a useful approach to identify potential risks in the chemotherapy medication process using either CPOE or paper-based prescriptions. The e-prescription mode was estimated to result in less risk than the traditional paper mode.
- Open Access
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S544-S545
964: First-trimester mean arterial blood pressure to predict the risk of preeclampsia
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S544-S545
Open Access964: First-trimester mean arterial blood pressure to predict the risk of preeclampsia